Art

J-GLOBAL ID：201002268066005823   Reference number：10A1100270

Management of chronic myeloid leukemia by imatinib

メシル酸イマチニブによる慢性骨髄性白血病のマネージメント

Author (1)： KIZAKI MASAHIRO (埼玉医科大学総合医療センター血液内科)
Material： 臨床血液  (Japanese Journal of Clinical Hematology)
Volume： 51  Issue： 10  Page： 1377-1385 (J-STAGE)  Publication year： 2010 
JST Material Number： Z0688A  ISSN： 0485-1439  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *antitumor drug ,...
Semi thesaurus term： tyrosine kinase inhibitor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A1100270&from=J-GLOBAL&jstjournalNo=Z0688A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Substance index (1)： STI-571

Reference (39)：

• 1) Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Eng J Med. 2003; 349: 1451-1464.
• 2) Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
• 3) Druker BJ, Talpatz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med. 2001; 344: 1031-1037.
• 4) O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic myeloid leukemia. N Eng J Med. 2003; 348: 994-1004.
• 5) Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med. 2006; 355: 2408-2417.

Terms in the title (3)： メシル酸イマチニブ ,  慢性骨髄性白血病 ,  マネージメント